RT Journal Article
SR Electronic
T1 <em>EGFR, SMAD7</em>, and <em>TGFBR2</em> Polymorphisms Are Associated with Colorectal Cancer in Patients with Lynch Syndrome
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5983
OP 5990
DO 10.21873/anticanres.12946
VO 38
IS 10
A1 ABRAM BUNYA KAMIZA
A1 WEN-CHANG WANG
A1 JENG-FU YOU
A1 REIPING TANG
A1 YEN-TING WANG
A1 HUEI-TZU CHIEN
A1 CHIH-HSIUNG LAI
A1 LI-LING CHIU
A1 TSAI-PING LO
A1 KUAN-YI HUNG
A1 CHAO AGNES HSIUNG
A1 CHIH-CHING YEH
YR 2018
UL http://ar.iiarjournals.org/content/38/10/5983.abstract
AB Background/Aim: Epidermal growth factor receptor (EGFR), mothers against decapentaplegic homolog 7 (SMAD7) and transforming growth factor betta (TGFB) are crucial for colorectal cancer (CRC) tumorigenesis. This study investigated whether polymorphisms in EGFR, SMAD7, and TGFB are associated with CRC risk in patients with Lynch syndrome. Materials and Methods: Genotyping was performed using Sequenom iPLEX MassArray. Association between genetic polymorphisms and CRC was assessed using a weighted Cox proportional hazard model. Results: Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17). The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype. Similarly, the GG genotype of TGFBR2 rs6785358 significantly increased the risk of CRC (HR=21.1, 95% CI=5.06-88.1) compared to the AA genotype. Conclusion: EGFR, SMAD7, and TGFBR2 are associated with CRC risk in patients with Lynch syndrome.